Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

Ed­i­tas Med­i­cine will elim­i­nate about 180 roles af­ter fail­ing to find a com­mer­cial part­ner for its ex­per­i­men­tal sick­le cell ther­a­py, and will halt de­vel­op­ment of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER